Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Total Liabilities (2019 - 2025)

Maxcyte (MXCT) has disclosed Total Liabilities for 6 consecutive years, with $33.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Liabilities fell 5.97% to $33.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $33.2 million, a 5.97% decrease, with the full-year FY2024 number at $33.2 million, down 8.0% from a year prior.
  • Total Liabilities was $33.2 million for Q3 2025 at Maxcyte, up from $29.0 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $36.1 million in Q4 2023 to a low of -$81.3 million in Q1 2021.
  • A 5-year average of $23.7 million and a median of $31.6 million in 2024 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: soared 138.79% in 2021, then dropped 8.0% in 2024.
  • Maxcyte's Total Liabilities stood at $21.2 million in 2021, then soared by 54.01% to $32.7 million in 2022, then increased by 10.47% to $36.1 million in 2023, then decreased by 8.0% to $33.2 million in 2024, then dropped by 0.05% to $33.2 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Total Liabilities are $33.2 million (Q3 2025), $29.0 million (Q2 2025), and $30.5 million (Q1 2025).